Literature DB >> 27785569

[Clostridium difficile infections in geriatric patients].

R Simmerlein1, A Basta2, M Gosch2.   

Abstract

Clostridium difficile is the main cause of nosocomial antibiotic-associated diarrhea in adults in Europe and North America. Infections with C. difficile typically occur in elderly patients with comorbidities and prior antibiotic therapy. Other risk factors are proton pump inhibitors, which are taken by many elderly patients. The main virulence factors are toxins A and B. The clinical spectrum ranges from asymptomatic colonization to severe disease with abdominal complications and sepsis. The current diagnostic gold standard is anaerobic culture but is impractical in routine use due to the long duration. Proven techniques involve glutamate dehydrogenase, toxins A and B immunoassays and PCR. First infections and recurrences can be treated with 400-500 mg metronidazole 3 times a day for 10 days. Further recurrences, serious infections or patients with more than two positive predictors should be treated orally with 125 mg vancomycin 4 times a day for at least 10 days. Fidaxomicin, rifaximin, stool transplantation and monoclonal antibodies are promising alternative therapies.

Entities:  

Keywords:  Antibodies; Metronidazole; Nosocomial infections; Pseudomembranous colitis; Ribotype; Vancomycin

Mesh:

Substances:

Year:  2016        PMID: 27785569     DOI: 10.1007/s00391-016-1143-9

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  111 in total

1.  Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.

Authors:  P Patrick Basu; Amreen Dinani; Krishna Rayapudi; Tommy Pacana; Niraj James Shah; Hemant Hampole; N V Krishnaswamy; Vinod Mohan
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  An outbreak of Clostridium difficile-associated disease (CDAD) in a German university hospital.

Authors:  K Graf; A Cohrs; P Gastmeier; A Kola; R-P Vonberg; F Mattner; D Sohr; I F Chaberny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-11-04       Impact factor: 3.267

Review 3.  The aging of the immune system.

Authors:  Daniela Weiskopf; Birgit Weinberger; Beatrix Grubeck-Loebenstein
Journal:  Transpl Int       Date:  2009-07-16       Impact factor: 3.782

4.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

5.  Clostridium difficile Infection.

Authors:  Daniel A Leffler; J Thomas Lamont
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

6.  IgG antibody response to toxins A and B in patients with Clostridium difficile infection.

Authors:  M Wullt; T Norén; A Ljungh; T Åkerlund
Journal:  Clin Vaccine Immunol       Date:  2012-07-11

7.  Rifaximin in the treatment of recurrent Clostridium difficile infection.

Authors:  E Mattila; P Arkkila; P S Mattila; E Tarkka; P Tissari; V-J Anttila
Journal:  Aliment Pharmacol Ther       Date:  2012-10-24       Impact factor: 8.171

8.  Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.

Authors:  B R Dalton; T Lye-Maccannell; E A Henderson; D R Maccannell; T J Louie
Journal:  Aliment Pharmacol Ther       Date:  2008-12-19       Impact factor: 8.171

9.  A case-control study of community-associated Clostridium difficile infection.

Authors:  M H Wilcox; L Mooney; R Bendall; C D Settle; W N Fawley
Journal:  J Antimicrob Chemother       Date:  2008-04-22       Impact factor: 5.790

Review 10.  Mammalian Rho GTPases: new insights into their functions from in vivo studies.

Authors:  Sarah J Heasman; Anne J Ridley
Journal:  Nat Rev Mol Cell Biol       Date:  2008-09       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.